- Home
- HRMY
as 11-15-2024 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 2.1B | IPO Year: | 2020 |
| Target Price: | $47.00 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.11 | EPS Growth: | -14.80 |
| 52 Week Low/High: | $26.03 - $41.61 | Next Earning Date: | 10-29-2024 |
| Revenue: | $681,879,000 | Revenue Growth: | 25.83% |
| Revenue Growth (this year): | 24.63% | Revenue Growth (next year): | 18.04% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Marshman Fund Trust II | HRMY | 10% Owner | Nov 1 '24 | Sell | $30.30 | 4,600,000 | $139,391,500.00 | 6,651,120 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Oct 29 '24 | Sell | $40.47 | 21,496 | $870,018.36 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Oct 3 '24 | Sell | $35.33 | 36,357 | $1,274,546.50 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Oct 1 '24 | Sell | $40.19 | 400 | $16,076.92 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Sep 30 '24 | Sell | $40.03 | 35,846 | $1,434,951.23 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Sep 27 '24 | Sell | $40.05 | 200 | $8,009.00 | 0 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Argus Research
5 days ago
HRMY: Rating increased to a BUY
Argus Research
12 days ago
HRMY: Lowering target price to $35.00
Simply Wall St.
12 days ago
There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings
Simply Wall St.
16 days ago
Earnings Beat: Harmony Biosciences Holdings, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Zacks
16 days ago
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Zacks
17 days ago
HRMY vs. REGN: Which Stock Is the Better Value Option?
Simply Wall St.
17 days ago
Harmony Biosciences Holdings Third Quarter 2024 Earnings: Beats Expectations
PR Newswire
17 days ago
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.